Gilead Sciences has bulked up its early-stage R&D portfolio with an agreement to buy XinThera, adding drugs targeting PARP for oncology and MK2 for inflammatory diseas
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl